Document is current
Any future updates will be listed below
-
Authors
Giraudet, Anne-Laure http://orcid.org/0000-0002-5366-1254
Cassier, Philippe Alexandre
Iwao-Fukukawa, Chicaco
Garin, Gwenaelle
Badel, Jean-Noël
Kryza, David
Chabaud, Sylvie
Gilles-Afchain, Laurence
Clapisson, Gilles
Desuzinges, Claude
Sarrut, David
Halty, Adrien
Italiano, Antoine
Mori, Masaharu
Tsunoda, Takuya
Katagiri, Toyomasa
Nakamura, Yusuke
Alberti, Laurent
Cropet, Claire
Baconnier, Simon
Berge-Montamat, Sandrine
Pérol, David
Blay, Jean-Yves
-
Funding
Funding for this research was provided by:
Canceropôle Lyon Auvergne Rhône-Alpes (PDC-N°22)
- License Information
-
More Information
Article History
Received: 31 August 2017
Accepted: 21 May 2018
First Online: 8 June 2018
Ethics approval and consent to participate
: This clinical trial protocol and amendments was approved by French competent Authority, ANSM on 12th October 2011 and by French Ethic committee (CPP Sud-Est IV, Lyon, France) on 13th September 2011 and conducted in accordance with International Conference on Harmonization for Good Clinical Practice, and local regulations (European Directive 2001/20/EC). All patients provided written informed consent. The study was registered on the ExternalRef removed website (NCT01469975).
: The manuscript does not contain data from any individual person and it is not applicable in this section.
: Chicaco Iwao-Fukukawa; Masaharu Mori, Takuya Tsunoda, Toyomasa Katagiri, Yusuke Nakamura were/are employees of Oncotherapy Science (Japan).Simon Baconnier was also an employee of OTS France.The remaining authors declare no competing interest with the study data.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
